Novartis Multiple Sclerosis Pill Loses “Some” Market Share
You Read, You Decide… A Link to the complete story is found below this abstract version of keynotes. Gilenya…
Biogen Idec seeks OK from the FDA for the next Oral MS Medication
The company asked the FDA to grant priority review for the pill, which would result in a decision in six…
Stuart Schlossman
Looking ahead at BG-12 – possibly the next oral medication for Multiple Sclerosis
Biogen presented positive data for its oral MS drug BG-12 last fall and plans to file for approval in the…
Stuart Schlossman
Treatment Advances for Multiple Sclerosis
For three decades Tracy Ofri, 48, of Valley Stream, N.Y., suffered with multiple sclerosis. At age 19, Ofri lost sight…
Stuart Schlossman
FDA Launches Gilenya Safety Review Following Patient Death
The U.S. Food & Drug Administration (FDA) is launching a Gilenya safety review after having recently receiving a report of…
Stuart Schlossman
Novartis drug Gilenya® showed positive clinical outcomes for relapsing-remitting MS
December 15, 2011 Novartis International AG / Novartis drug Gilenya® showed positive clinical outcomes for relapsing-remitting MS patients in third…
Stuart Schlossman
Even with Limited European Access, Gilenya Trial and Uptake Is Having a Significant Impact on the EU5 DMA Market Landscape
EXTON, Penn.–(BUSINESS WIRE)–While neurologists in the EU5 countries (France, Germany, Italy, UK, and Spain) report being most satisfied with Tysabri,…
Stuart Schlossman
Promising Multiple Sclerosis Treatment Targets Immune Cells to Increase Neuroprotection, Study Shows
ScienceDaily (Dec. 6, 2011) — Laquinimod is an orally available synthetic compound that has been successfully evaluated in phase II/III clinical…
Stuart Schlossman
Seventy-Four Percent of Surveyed U.S. Neurologists Indicate They Will Prescribe Biogen Idec’s BG-12 for the Treatment of Relapsing-Remitting Multiple Sclerosis
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that 74 percent…
Stuart Schlossman
Progressive MS Update: Opexa’s Tovaxin(R) for the Treatment of Multiple Sclerosis Granted Fast Track Designation by FDA
THE WOODLANDS, Texas, Nov 08, 2011 (BUSINESS WIRE) — Opexa Therapeutics, Inc. announced today that its lead drug candidate Tovaxin(R) has…
Stuart Schlossman
